JP2003277289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003277289A5 JP2003277289A5 JP2002376997A JP2002376997A JP2003277289A5 JP 2003277289 A5 JP2003277289 A5 JP 2003277289A5 JP 2002376997 A JP2002376997 A JP 2002376997A JP 2002376997 A JP2002376997 A JP 2002376997A JP 2003277289 A5 JP2003277289 A5 JP 2003277289A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- same
- salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 description 32
- 150000003839 salts Chemical class 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002376997A JP4353697B2 (ja) | 2001-12-27 | 2002-12-26 | がんの予防・治療剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-398165 | 2001-12-27 | ||
| JP2001398165 | 2001-12-27 | ||
| JP2002376997A JP4353697B2 (ja) | 2001-12-27 | 2002-12-26 | がんの予防・治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003277289A JP2003277289A (ja) | 2003-10-02 |
| JP2003277289A5 true JP2003277289A5 (enExample) | 2006-01-26 |
| JP4353697B2 JP4353697B2 (ja) | 2009-10-28 |
Family
ID=29252843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002376997A Expired - Fee Related JP4353697B2 (ja) | 2001-12-27 | 2002-12-26 | がんの予防・治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4353697B2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1701736A4 (en) * | 2003-12-24 | 2008-05-07 | Inst Medical W & E Hall | THERAPEUTIC AGENTS AND USES |
-
2002
- 2002-12-26 JP JP2002376997A patent/JP4353697B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010508369A5 (enExample) | ||
| JP2010518006A5 (enExample) | ||
| RU2007136026A (ru) | Варианты ил-21 | |
| IL147271A (en) | Isolated peptide ligands that bind to her2 | |
| MXPA02011379A (es) | Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb. | |
| AU2001272735A1 (en) | Novel physiologically active peptide and use thereof | |
| WO2002087507A3 (en) | Breast cancer-associated genes and uses thereof | |
| WO2003013534A3 (en) | Methods for the treatment of cancer with irinotecan based on cyp3a5 | |
| JP7495390B2 (ja) | Ｆｇｆｒ１変異陽性脳腫瘍を治療するための医薬組成物及び治療方法 | |
| WO2001055178A3 (en) | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer | |
| CN111542326B (zh) | 转铁蛋白受体(TfR)的RNA适体 | |
| CN101970457A (zh) | Iap抑制剂 | |
| WO2004062574A3 (en) | Improved linkers for radiopharmaceutical compounds | |
| EA200501197A1 (ru) | Композиции и способы для лечения злокачественной опухоли с применением igsf9 и liv - 1 | |
| JP2003277289A5 (enExample) | ||
| JP2003277288A5 (enExample) | ||
| Tanaka et al. | Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma | |
| WO2002070559A3 (en) | Nuclear hormone receptor ligand binding domains | |
| WO2005023186A3 (en) | Methods of identifying agents that inhibit the growth of cancer cells | |
| TW200517125A (en) | Pharmaceutical composition for treatment of solid cancers | |
| US10610514B2 (en) | Composition comprising compound inhibiting interactions of MBD2 and P66α for anti-metastasis and prevention and treatment of cancer disease | |
| JP2002355060A5 (enExample) | ||
| US7799753B2 (en) | Bisubstrate inhibitors of protein tyrosine kinases as therapeutic agents | |
| MXPA02010813A (es) | Fosforamidatos de bis-(n,n'-bis-(2-haloetil)amino) como agentes antitumor. | |
| EP3984547A1 (en) | Peptides for the treatment of cancer |